Cantor Fitzgerald reiterated its Overweight rating on ORIC Pharmaceuticals (NASDAQ:ORIC), currently trading at $13.39, after an incident involving a potential news leak. According to InvestingPro data ...

Eric Johnston, Cantor Fitzgerald chief equity and macro strategist, joins 'Money Movers' to discuss Johnston's thesis for ...

Cantor Fitzgerald started coverage on shares of Amentum (NYSE:AMTM – Free Report) in a report issued on Friday, Marketbeat.com reports. The brokerage issued a neutral rating and a $25.00 target price ...

ORIC Pharmaceuticals Inc. (NASDAQ: ORIC) shares rose 12% following a recommendation from Cantor Fitzgerald to buy shares amid a possible leak of encouraging clinical trial data. Analyst Prakhar ...

Cantor Fitzgerald started coverage on shares of Science Applications International (NYSE:SAIC – Free Report) in a research ...

In a report released yesterday, Troy Jensen from Cantor Fitzgerald reiterated a Buy rating on Proto Labs (PRLB – Research Report), with a price ...

We recently compiled a list of the 9 Must-See AI News Updates That Are Trending on Wall Street. In this article, we are going to take a look at where BigBear.ai Holdings, Inc.

We recently published a list of 9 Trending AI News Updates on Wall Street’s Radar. In this article, we are going to take a look at where AST SpaceMobile, Inc.

Will the Senate GOP confirm controversial picks like Tulsi Gabbard and RFK Jr.? Here’s the hearings schedule and list of ...

In a report released yesterday, Matthew Prisco from Cantor Fitzgerald maintained a Buy rating on Onto Innovation (ONTO – Research Report), with ...